Clofibric Acid 882-09-7

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

214.65 Clofibric acid is a PPARα agonist and hypolipidemic agent.






Biological Activity


Clofibric acid increases CYP4A6 gene expression in RK13 cells transfected with PPAR-G with EC50 of 80 μM. Clofibric acid (1 mM) treatment for 4 days induces 500-fold increase of
P450 4Al RNA and 280-fold increase of acyl-CoA oxidase and P450 2Bl RNA
in hepatocytes, relative to control cultures. Clofibric
acid (250 μM) induces up-regulation of genes involved in peroxisome
proliferation and in cell proliferation as well as down-regulation of
genes involved in Apoptosis in hepatocytes of rodent.


Clofibric acid
treatment is able to cause up-regulation of L-fatty acid binding protein
(L-FABP) gene in hepatocytes of both rodent and human origin. Clofibric
acid also up-regulates genes expression of the cytosolic, microsomal,
and mitochondrial pathways involved in fatty acid transport and
Metabolism in both rodent and human hepatocyte cultures, and increases
genes level of the peroxisomal pathway of lipid metabolism in rodents.


An up-regulation of hepatocyte nuclear factor 1α (HNF 1α) by Clofibric
acid is observed in human hepatocyte cultures. Clofibric
acid also dose-dependently inhibits cell proliferation of cultured
OVCAR-3 and DISS cells derived from human ovarian cancer. Clofibric acid
treatment increases the expression of carbonyl reductase, which
promotes the conversion of prostaglandin E2 (PGE2) to PGF 2α.


Clofibric acid (50 mg/kg) treatment 4 days by gavage induces both P450
4A and BFB expression in zones 3 and 2 of the liver acinus in rats. 300
mg/kg of Clofibric acid causes a strong staining of both Proteins
throughout the liver acinus. Clofibric acid (9,000 ppm)
treatment in diet significantly suppresses the growth of OVCAR-3 tumors
xenotransplanted s.c. (46%) and significantly prolongs the survival of
mice with malignant ascites derived from DISS cells as compared with
control.


Clofibric acid treatment increases the expression of carbonyl
reductase in vivo. Clofibric acid treatment decreases PGE2 level as well
as vascular endothelial growth factor (VEGF) amount in both of
OVCAR-3–tumor and DISS-derived ascites. Reduced microvessel density and
induced apoptosis are in solid OVCAR-3 tumors treated by Clofibric acid.

Contact us if you need more details on 882-09-7. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Clofibric Acid 882-09-7、882-09-7 Clofibric Acid. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Metabolism > PPAR Inhibitor